

Release No 101

23 May 2003

Statement of shares in H. Lundbeck A/S held by insiders

Lundbeck hereby submits a statement of shares held by the company's insiders in pursuance of section 37(8) of the Danish Securities Trading Act. According to this statutory provision, H. Lundbeck A/S is obliged to provide quarterly information on shares in H. Lundbeck A/S held by insiders and connected persons.

Securities code:	Holding (number)	Market value (DKK)
DK0010287234	As at 23 May 2003	As at 23 May 2003
Supervisory Board (incl. related parties)	38,952	4,879,127.52
Board of Management (incl. related parties)	194,237	24,330,126.62
All (incl. related parties)	537,092	67,276,143.92

Definition of insiders

Lundbeck defines insiders as members of the company's Board of Directors and Board of Management, directors, functional managers, managers of subsidiaries, employees in Investor Relations & Corporate Reporting, and employees in the Legal Department. In addition, a large number of other persons, who have access to insider information through their work, have been categorised as insiders. This group comprises some 220 persons in Lundbeck's insider register.

The group of insiders comprises insiders and connected persons.

Connected persons are defined as:

- spouses or cohabitants,
- children under the age of 18, and
- companies in which the insider holds a controlling interest.

The group of insiders and connected persons comprises some 600-900 names in total.

The content of this release will have no influence on the Lundbeck Groups result for 2003. The company expects an increase in revenue of



approximately 10% compared to 2002, while the operating profit is expected to increase by approximately 12% compared to 2002.

For further information please contact Hans Henrik Munch-Jensen, CFO, tel +45 36 30 15 11, ext. 32660, Steen Juul Jensen, Director of Investor Relations & Corporate Reporting, tel +45 36 43 30 06, or Jacob Tolstrup, Investor Relations Officer, tel +45 36 43 30 79.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2002, the Companys revenue was DKK 9.5 billion. The number of employees is approx. 5,500.